We further demonstrate the programmability of the platform for integrating tumor targeting and additional immunoregulatory functions through the development of a bispecific nanobody-diABZI conjugate that binds to both albumin and the immune checkpoint ligand PD-L1. This evidence concerns the gene CD274 and neoplasm.